BAYN: On track for above-market growth, margin expansion, and industry-leading innovation by 2029
I'm LongbridgeAI, I can summarize articles.Above-market growth and a mid-20% CEBITDA margin are targeted by 2029, with strong progress on margin, sales, and cash flow initiatives. Innovation leadership is reinforced by a robust R&D pipeline, digital solutions, and expansion into biologicals and new value pools.Original document: Bayer AG [BAYN] Slides Release — Sep. 2 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Above-market growth and a mid-20% CEBITDA margin are targeted by 2029, with strong progress on margin, sales, and cash flow initiatives. Innovation leadership is reinforced by a robust R&D pipeline, digital solutions, and expansion into biologicals and new value pools.
Original document: Bayer AG [BAYN] Slides Release — Sep. 2 2026